Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.

As a pioneer in diabetes care, Novo has been in the business for over 85 years and claims 34% of the $80 billion-plus diabetes treatment market and roughly half of the more than $15 billion ...

Novo Nordisk, however, forecast slower sales growth for 2025 of between 16% to ... work by mimicking a hormone called glucagon-like peptide-1, which suppresses appetite. Investors are now watching ...

Danish drugmaker Novo Nordisk (NVO) reported fourth quarter ... But Novo said Wednesday it expects slower growth in 2025 compared to the prior year. The 2024 outlook estimated growth between ...